The Food and Drug Administration (FDA) warns all healthcare professional and the general public on the voluntary recall of Endo GIA™ Articulating Reload with Tri-Staple™ Technology with MDR No. 00768, imported and distributed by Medtronic Philippines Inc.:
| Product Name | Product Code | Lot Number |
| Endo GIA™ Articulating Reload with Tri-Staple™ Technology | EGIA60AMT | N5G0186KX |
| N5J0492KX | ||
| N5J0775KX | ||
| N5M0769KX | ||
| N5M0582KX | ||
| N6C0972KX | ||
| N6E0462KX | ||
| N6E0600KX | ||
| N6F0541KX |
Medtronic Philippines Inc. has conducted the voluntary recall of the aforementioned product due to the potential absence of one of the two pin components that maintains the alignment of the device jaws. This potential issue was identified during the in-process quality testing at the manufacturing facility. The use of a product with missing pin may result in incomplete staple formation. This may cause bleeding, anastomotic leak, peritonitis, or pneumothorax which can result in the potential for infection and/or sepsis. Manufacturing process improvements have been implemented to address this issue. There have been no confirmed complaints associated with this recall.
In light of the foregoing, all concerned healthcare professional, establishment, and the general public is warned to discontinue further use, sale, and distribution of the said medical device.
All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that product is not sold or made available in the market or areas of jurisdiction.
To report any sale or distribution of unregistered medical device, the online reporting facility, eReport can be accessed at www.fda.gov.ph/ereport.
Any suspected adverse reaction experienced from the use of the medical device but not limited to the lot numbers stated above should be reported immediately to FDA.
For more information and inquiries, kindly contact the FDA Center for Device Regulation, Radiation Health, and Research through e-mail at [email protected], or call (02) 857-1900 loc. 8301.
Dissemination of this advisory to all concerned is hereby requested.
Attachment:-> FDA Advisory No.2019-523